Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update
24.03.2023 - - Enrollment Nearing Completion in Human Acellular Vessel (HAV) Phase 2/3 Trial in Vascular Trauma and Phase 3 Trial in Arteriovenous (AV) Access in Hemodialysis Patients - Multiple publications and scientific meeting presentations highlighting ...
Source: wallstreet-online.de